Nirmal Bang has recommended hold rating on Glenmark Pharmaceuticals with a target price of Rs 556, in its January 30, 2013 research report.
In CNBC-TV18's popular show Bull's Eye, Parag Doctor, Keynote Capital shares trading strategy of the day.
Drug firm Glenmark Pharmaceuticals today said it has received US health regulator's approval to market Mupirocin Calcium Cream, used for treating skin diseases, in the American market.
Nirmal Bang has come out with its earnings estimates for pharmaceutical sector for the quarter ended December 2012. The research firm feels margins of pharma companies may witness YoY expansion owing to rupee depreciation (6 percent YoY).
Leading stock exchange BSE today announced changes in its indices for the mid-cap and small-cap segments, which will come into effect from January 14.
Drug firm Glenmark Pharmaceuticals today said US health regulator has granted marketing approval to its US partner Salix Pharmaceuticals for Crofelemer tablets used for treating diarrhoea in HIV patients.
Shares in Glenmark Pharmaceuticals gain 2.5 percent after US health regulators approved Salix Pharmaceuticals Ltd's drug to treat diarrhoea in HIV/AIDS patients on qantiretroviral therapy, a combination of medicines used to treat HIV infection.
Glenmark Pharmaceuticals shot up as much as 5 percent to touch a four-year high of Rs 546.60 on Wednesday on Morgan Stanley report.
Glenmark Pharmaceuticals on Thursday said it is aiming for up to 30 percent growth in revenues this fiscal to touch Rs 5,000 crore, with the US and Latin America expected to be primary contributors.
India approved a new drug pricing policy designed to increase the number of drugs deemed essential that are subject to price caps, two ministers told reporters.
Glenmark Pharmaceuticals today said it has settled litigation with Janssen Pharmaceuticals Inc over patent actions regarding generic oral contraceptive Norgestimate and Ethinyl Estradiol tablets.
Glenmark Pharmaceuticals today said it has received tentative approval from the US health regulator for its generic Rizatriptan Benzoate tablets used for treating migraine attacks.
GLENMARK-FIRING-ON-ALL-CYLINDERS-JPMORGAN:Glenmark 'firing on all cylinders' - J.P.Morgan
An international arbitrator ruled that India's Glenmark Pharmaceuticals has the right to sell its HIV-associated diarrhoea drug Crofelemer in 140 countries.
Glenmark Pharmaceuticals in its meeting held on May 08 has recommended dividend at 200% i.e. 2 per share on the equity share capital for the financial year 2011-2012 subject to the approval of the shareholders at the ensuing Annual General Meeting.
Shares in major drug makers gain on expectations for strong April-June earnings.
Glenmark Pharmaceuticals has recalled seven batches of oral contraceptive tablets norgestimate and ethinyl estradiol from the United States following a packaging error, the drugmaker said on Saturday.
Sushil Finance is bullish on Glenmark Pharmaceuticals and has recommended buy rating on the stock with a target price of Rs 368 in its February 9, 2012 research report.
Pharma major Glenmark Pharmaceuticals today said it has appointed Sandeep Gupta as Chief Operating Officer (COO) and Michael Buschle as Chief Scientific Officer (CSO).
Glenmark Pharmaceuticals said on Tuesday it has sought an arbitration in the US as Napo Pharmaceuticals has no basis for terminating a collaboration agreement with it to develop and market an HIV-associated diarrhoea drug.
Deven Choksey, MD, KR Choksey Securities share his view on Reliance Industries.
Glenmark Generics Inc USA has received tentative approval from US Food and Drugs Administration for Montelukast Sodium 10 mg tablets, a generic version of pharma major Merck's Singulair tablets.
Nirmal Bang has recommended hold rating on Glenmark Pharmaceuticals with a target price of Rs 358, in its November 18, 2011 research report.
PINC Research is bullish on Glenmark Pharmaceuticals and has recommended buy rating on the stock with a target price of Rs 360 in its November 10, 2011 research report.
Nirmal Bang has come out with its report on pharma space. Torrent Pharma and Glenmark Pharma owing to their discounted valuations and strong earnings trajectory are top Buy ideas, while Sun Pharmaceutical’s near-term growth looks fully priced in and therefore gets our Hold rating. We assign a Sell rating on Cipla and Cadila Healthcare.